The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab co...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mult Scler
Main Authors: van Kempen, Zoé LE, Leurs, Cyra E, Witte, Birgit I, de Vries, Annick, Wattjes, Mike P, Rispens, Theo, Killestein, Joep
格式: Artigo
語言:Inglês
出版: SAGE Publications 2017
主題:
Original Research Papers
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971363/
https://ncbi.nlm.nih.gov/pubmed/28485678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517708464
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍